Governance
COMPANY ARTICLES
Please find the newest company articles here: BioPorto A/S – Articles of Association
CORPORATE GOVERNANCE
BioPorto is subject to the recommendations prepared by the Committee on Corporate Governance, which are available at www.corporategovernance.dk.
The Board of Directors regularly assesses how the recommendations may contribute to strengthening the management of BioPorto and ensure maximum value creation for the company’s shareholders. Once a year, the Board of Directors reviews the recommendations, evaluating BioPorto’s degree of compliance. The Board of Directors believes that BioPorto complies with all of the recommendations of the Committee.
The Statutory report on Corporate Governance is attached below.
The Statutory reports on Corporate Governance 2012 – 2021:
Corporate Governance 2017.pdf God Selskabsledelse 2017.pdf
Corporate Governance 2016.pdf God Selskabsledelse 2016.pdf
Corporate Governance 2015.pdf God Selskabsledelse 2015.pdf
Corporate Governance 2014.pdf God Selskabsledelse 2014.pdf
Corporate Governance 2013.pdf God Selskabsledelse 2013.pdf
Corporate Governance 2012.pdf God Selskabsledelse 2012.pdf
CORPORATE SOCIAL RESPONSIBILITY
BioPorto is aware of its corporate social responsibility and endeavors to improve social and environmental conditions. In addition, the corporate social responsibility report is provided in BioPorto’s Annual Report. BioPorto has signed the UN Global Compact, and the latest Communication on Progress, which is available here.
REMUNERATION POLICY AND GUIDELINES FOR INCENTIVE-BASED REMUNERATION
Remuneration policy and guidelines for incentive-based remuneration of the board of directors and executive management of BioPorto A/S.
These Guidelines have been prepared pursuant to the Recommendations on Corporate Governance, Recommendation 4 and section 139 of the Danish Companies Act, according to which BioPorto A/S must prepare a remuneration policy and guidelines for incentive remuneration covering the Company’s Board of Directors and Executive Management, where “Executive Management” is defined as the Manager(s) registered with the Danish Business Authority as Manager(s) of the Company.
The Guidelines were approved at the Annual General Meeting of BioPorto A/S on April 29, 2021.
The guidelines are presented for the general meeting’s approval at least every four years and upon significant changes.
Information about the current remuneration of the Company’s Board of Directors and Executive Management is found in the annual report, which is also available on the annual report section of this website.
Remuneration policy and guidelines for incentive-based remuneration.pdf
Vederlagspolitik og retningslinjer for incitamentsaflønning.pdf
RISK MANAGEMENT
BioPorto carries out development and sales activities in the area of diagnostics. Through its activities, the Group is exposed to a number of risks that could significantly affect its operations in the event these risks are not correctly assessed and managed. BioPorto’s policy is to identify and mitigate risks deriving from the Group’s operations and to establish adequate insurance coverage. BioPorto has established risk management as a formalized process for the purpose of generating a close connection between the Group’s ongoing objectives and activities and the individual risk elements within the Group’s sphere of activity. In connection with the new corporate strategy, Management has specifically addressed risks relating to new objectives. Follow this link to learn more: Risk Management
BOARD MEMBERS
Individual board member biographies can be found on About BioPorto.
Summary
2022 Board Member |
First Elected |
Term Expires |
Independent |
Nationality |
Year of Birth |
Gender |
Christopher Lindop |
2019 |
2023 |
Yes |
USA |
1957 |
M |
John McDonough |
2021 |
2023 |
Yes |
USA |
1959 |
M |
Don Hardison |
2021 |
2023 |
Yes |
USA |
1950 |
M |
Michael Singer |
2019 |
2023 |
Yes |
USA |
1973 |
M |
Jan Leth Christensen |
2021 |
2023 |
Yes |
Denmark |
1963 |
M |
Peter Mørch Eriksen |
2021 |
2023 |
No* |
Denmark |
1960 |
M |
2022 Meetings |
Board of Directors |
Remuneration Committee |
Nomination Committee |
Audit Committee* |
Strategy Committee |
Business, Research and Development Committee |
| Chair |
Christopher Lindop |
Don Hardison |
Christopher Lindop |
John McDonough |
Christopher Lindop |
Michael Singer |
| Christopher Lindop | 20/20 | 1/3 | 1/1 | 6/6 | 5/5 | 1/1 |
| John McDonough | 19/20 | 2/3 | 1/1 | 6/6 | 5/5 | 1/1 |
| Don Hardison | 20/20 | 2/3 | 0/1 | 5/5 | 1/1 | |
| Michael Singer | 19/20 | 6/6 | 5/5 | 1/1 | ||
| Jan Leth Christensen | 19/20 | 5/5 | 1/1 | |||
| Peter Mørch Eriksen | 20/20 | 5/5 | 1/1 |
*Includes one meeting with the external Auditors.
Participation in Committee Meetings are compensated with an additional remuneration of DKK 25,000 per Committee per year, with an overall maximum of DKK 50,000 per Board Member. The Chairman and Vice-Chairman are not entitled to receive additional remuneration for Committee membership.
BOARD COMMITTEES
BioPorto’s Board Committees are preparatory bodies to assist the Board of Directors in its work and shall provide oversight and monitoring functions over the business.
DIVERSITY POLICY
BioPorto is committed to ensuring and furthering equal opportunities for all employees in respect of differences, such as gender, age, religion, sexual orientation and ethnicity, as all, in our view, serve as key components in ensuring a better, more dynamic and healthier business. We believe that employees should be recognized because of, not despite, their diversity. The view extended through this policy also includes maintaining equal opportunities for women and men at all management levels in the BioPorto group. The Board of Directors annually discusses the Company’s activities to ensure relevant diversity at management levels and evaluates the policy on diversity.
DATA PROTECTION POLICY
BioPorto complies with the European GDPR rules, which gives individuals a number of rights. For more information regarding the use of this site, privacy, and legal/compliance policies, please refer to the following: